NovoCure Limited (NVCR)
NASDAQ: NVCRHealthcareMedical DevicesUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 14.66 0.00%
NVCR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.71B
- EPS (TTM)
- -$1.30
- Dividend yield
- None
- 52-week range
- 9.82 – 21.45
- Day range
- 14.59 – 15.12
- Volume / Avg
- 2.99M / 1.42M
- Beta
- —
- Shares outstanding
- 116.45M
- Next earnings
- Oct 29, 2026
52-week range
NVCR stock today
Shares of NovoCure (NVCR) finished lower on Oct 7 at $14.66, a drop of 2.07% or $0.31 per share, versus the S&P 500's 0.22% decline. Volume was 2.1x the average at 2.99M shares, a sign of unusually heavy trading. Shares are 31.7% below their 52-week high of $21.45, set on Jul 24, 2026 and 49.3% above the 52-week low of $9.82, in the middle of the past year's range.
NVCR is up 13.4% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 3.5%. NovoCure has posted a net loss over the last twelve months (EPS of -$1.30), so its P/E ratio is not meaningful. NovoCure's next earnings report is expected on Oct 29, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About NovoCure
Company profileNovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
- Sector
- Healthcare
- Industry
- Medical Devices
- CEO
- Mr. Frank Leonard
- Headquarters
- Baar
- Employees
- 1,605
- IPO year
- 2015
- Website
- novocure.com
Analyst forecast
ForecastConsensus (7 analysts)
buy
Avg. price target
$26.86+83.22%
- Strong buy 1
- Buy 3
- Hold 3
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 29, 2026
- EPS estimate
- $-0.21
NovoCure peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ESTAEstablishment Labs Holdings Inc. | 63.85 | -2.21% | $1.90B | vs NVCR |
| ATECAlphatec Holdings Inc. | 10.25 | -2.75% | $1.58B | vs NVCR |
| ALMRAlamar Biosciences Inc. | 27.77 | -13.92% | $1.93B | vs NVCR |
| INSPInspire Medical Systems Inc. | 67.45 | -1.10% | $1.95B | vs NVCR |
| AXGNAxogen Inc. | 36.04 | -0.74% | $2.11B | vs NVCR |
| BFLYButterfly Network Inc. Class A | 8.27 | -4.94% | $2.20B | vs NVCR |
| UFPTUFP Technologies Inc. | 292.87 | -3.30% | $2.27B | vs NVCR |
| NEOGNeogen Corporation | 11.68 | -2.34% | $2.55B | vs NVCR |
Indexes, lists and sector
Appears in lists
NovoCure stock FAQ
What is NovoCure's stock price today?
NVCR last traded at $14.66 as of Oct 7, 4:00 PM EDT, down 2.07% on the day. Prices are delayed at least 15 minutes.
When is NovoCure's next earnings date?
NovoCure is expected to report earnings on Thursday, October 29, 2026. Analysts expect EPS of $-0.21.
Who is NovoCure's CEO?
Mr. Frank Leonard is the chief executive officer of NovoCure Limited, which has about 1,605 employees.
What is the NVCR 52-week high?
The 52-week high for NVCR is $21.45 and the 52-week low is $9.82. The stock is currently 31.7% below its high.